Search

Your search keyword '"José Manuel Quesada-Gómez"' showing total 3 results
Start Over Author "José Manuel Quesada-Gómez" Publisher oxford university press
3 results on '"José Manuel Quesada-Gómez"'

1. Response to Letter to the Editor from Viola Viola: 'Calcifediol treatment and COVID-19-related outcomes'

Author

José Manuel Quesada-Gómez, Xavier Nogués, and Natalia Garcia-Giralt

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Letter to the editor, Coronavirus disease 2019 (COVID-19), Endocrinology, Diabetes and Metabolism, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clinical Biochemistry, Biochemistry, chemistry.chemical_compound, Endocrinology, COVID-19 (Malaltia) -- Tractament, Internal medicine, Medicine, Humans, Viola (butterfly), Calcifediol, biology, business.industry, SARS-CoV-2, Biochemistry (medical), COVID-19, Letter to the Editor Response, biology.organism_classification, Dermatology, chemistry, business, AcademicSubjects/MED00250
Published
2021

2. Calcifediol treatment and COVID-19-related outcomes

Author

Anna Ribes, José Manuel Quesada-Gómez, Campodarve I, Marta Pineda-Moncusí, Jaime Rodriguez-Morera, Maria Lourdes Cos, Natalia Garcia-Giralt, Carme Gimenez-Argente, Diana Ovejero, Abora Rial, Dolors Arenas, Roger Bouillon, Xavier Nogués, Julio Pascual, Judit Villar-García, and Robert Güerri-Fernández

Subjects
Adult, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, 030209 endocrinology & metabolism, Context (language use), Comorbidity, Logistic regression, Biochemistry, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Intensive care, Internal medicine, Vitamin D and neurology, Humans, Medicine, Hospital Mortality, 030212 general & internal medicine, Mortality, Vitamin D, Aged, Cholecalciferol, Calcifediol, ICU admission, SARS-CoV-2, business.industry, Biochemistry (medical), COVID-19, Odds ratio, Middle Aged, Vitamin D Deficiency, mortality, COVID-19 Drug Treatment, Hospitalization, Intensive Care Units, Treatment Outcome, chemistry, Spain, Female, business, Cohort study
Abstract

Context COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity. Objective This work aims to elucidate the effect of 25(OH)D3 (calcifediol) treatment on COVID-19–related outcomes. Methods This observational cohort study was conducted from March to May 2020, among patients admitted to COVID-19 wards of Hospital del Mar, Barcelona, Spain. A total of 930 patients with COVID-19 were included; 92 were excluded because of previous calcifediol intake. Of the remaining 838, a total of 447 received calcifediol (532 μg on day 1 plus 266 μg on days 3, 7, 15, and 30), whereas 391 were not treated at the time of hospital admission (intention-to-treat). Of the latter, 53 patients were treated later during ICU admission and were allocated in the treated group in a second analysis. In healthy individuals, calcifediol is about 3.2-fold more potent on a weight basis than cholecalciferol. Main outcome measures were ICU admission and mortality. Results ICU assistance was required by 102 (12.2%) participants. Out of 447 patients treated with calcifediol at admission, 20 (4.5%) required the ICU, compared to 82 (21%) out of 391 nontreated (P Conclusion In patients hospitalized with COVID-19, calcifediol treatment significantly reduced ICU admission and mortality.

Published
2021

3. Vitamin D Endocrine System and COVID‐19

Author

Roger Bouillon and José Manuel Quesada‐Gomez

Subjects
VITAMIN D, CALCIFEDIOL, COVID‐19, MORTALITY, ACUTE RESPIRATORY DISTRESS SYNDROME, INTENSIVE CARE TREATMENT, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935
Abstract

ABSTRACT Preclinical data strongly suggest that the vitamin D endocrine system (VDES) may have extraskeletal effects. Cells of the immune and cardiovascular systems and lungs can express the vitamin D receptor, and overall these cells respond in a coherent fashion when exposed to 1,25‐dihydroxyvitamin D, the main metabolite of the VDES. Supplementation of vitamin D‐deficient subjects may decrease the risk of upper respiratory infections. The VDES also has broad anti‐inflammatory and anti‐thrombotic effects, and other mechanisms argue for a potential beneficial effect of a good vitamin D status on acute respiratory distress syndrome, a major complication of this SARS‐2/COVID‐19 infection. Activation of the VDES may thus have beneficial effects on the severity of COVID‐19. Meta‐analysis of observational data show that a better vitamin D status decreased the requirement of intensive care treatment or decreased mortality. A pilot study in Cordoba indicated that admission to intensive care was drastically reduced by administration of a high dose of calcifediol early after hospital admission for COVID‐19. A large observational study in Barcelona confirmed that such therapy significantly decreased the odds ratio (OR) of mortality (OR = 0.52). This was also the conclusion of a retrospective study in five hospitals of Southern Spain. A retrospective study on all Andalusian patients hospitalized because of COVID‐19, based on real‐world data from the health care system, concluded that prescription of calcifediol (hazard ratio [HR] = 0.67) or vitamin D (HR = 0.75), 15 days before hospital admission decreased mortality within the first month. In conclusion, a good vitamin D status may have beneficial effects on the course of COVID‐19. This needs to be confirmed by large, randomized trials, but in the meantime, we recommend (rapid) correction of 25 hydroxyvitamin D (25OHD) deficiency in subjects exposed to this coronavirus. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results